Target and Technology

Denintuzumab mafodotin (SGN-CD19A; 19A) targets CD19, a protein widely found on B-cell hematologic malignancies. It is comprised of an anti-CD19 monoclonal antibody linked to our proprietary cell-killing agent, monomethyl auristatin F (MMAF).

ADC technology combines the specificity of monoclonal antibodies, innovative linker systems, and the cell killing power of potent cytotoxic agents to treat cancer. Using our proprietary industry-leading technology, we are able to optimize each ADC to potentially improve outcomes for patients.

Clinical Development Status

  • Two phase 2 trials evaluating denintuzumab mafodotin in relapsed/refractory and frontline diffuse large B-cell lymphoma (DLBCL) are currently enrolling

Proposed Mechanism of Action

MMAF_release_19A_r12.jpg 

Denintuzumab mafodotin (SGN-CD19A; 19A) is an investigational agent, and its safety and efficacy have not yet been established.